Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997965 · ClinicalTrials.gov registry record · Phase 4
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
A Phase 4 study, sponsored by Alimentiv.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT06997965 is a Phase 4 study that is actively recruiting participants, run by Alimentiv. The registered enrollment target is 60 participants.
The verdict
NCT06997965, a Phase 4 study, is actively recruiting participants, sponsored by Alimentiv.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06997965
The ClinicalTrials.gov registry entry for NCT06997965 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alimentiv, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT06997965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06997965 about?
NCT06997965 is a clinical study titled "Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD". This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
What is the current status of trial NCT06997965?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-04-20. Estimated completion is 2028-04-01.
What interventions are being tested in trial NCT06997965?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06997965?
This trial is sponsored by Alimentiv, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.